A pilot study is underway to quantify in vivo the uptake and distribution of Tc-99m Sestamibi in subjects without previous history of breast cancer using a dedicated SPECT-CT breast imaging system. Subjects undergoing diagnostic parathyroid imaging studies were consented and imaged as part of this IRB-approved breast imaging study. For each of the seven subjects, one randomly selected breast was imaged prone-pendant using the dedicated, compact breast SPECT-CT system underneath the shielded patient support. Iteratively reconstructed and attenuation and/or scatter corrected images were coregistered; CT images were segmented into glandular and fatty tissue by three different methods; the average concentration of Sestamibi was determined from the SPECT data using the CT-based segmentation and previously established quantification techniques. Very minor differences between the segmentation methods were observed, and the results indicate an average image-based in vivo Sestamibi concentration of 0.10 ± 0.16 μCi/mL with no preferential uptake by glandular or fatty tissues. © 2012 Steve D. Mann et al.
CITATION STYLE
Mann, S. D., Perez, K. L., McCracken, E. K. E., Shah, J. P., Wong, T. Z., & Tornai, M. P. (2012). Initial in vivo quantification of Tc-99m Sestamibi uptake as a function of tissue type in healthy breasts using dedicated breast SPECT-CT. Journal of Oncology. https://doi.org/10.1155/2012/146943
Mendeley helps you to discover research relevant for your work.